[go: up one dir, main page]

CA2329129A1 - Formulations geniques stables - Google Patents

Formulations geniques stables Download PDF

Info

Publication number
CA2329129A1
CA2329129A1 CA002329129A CA2329129A CA2329129A1 CA 2329129 A1 CA2329129 A1 CA 2329129A1 CA 002329129 A CA002329129 A CA 002329129A CA 2329129 A CA2329129 A CA 2329129A CA 2329129 A1 CA2329129 A1 CA 2329129A1
Authority
CA
Canada
Prior art keywords
saccharides
formulations
stable gene
gene formulations
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002329129A
Other languages
English (en)
Other versions
CA2329129C (fr
Inventor
Masaaki Terada
Takahiro Ochiya
Akihiko Sano
Akihiko Hisada
Shunji Nagahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2329129A1 publication Critical patent/CA2329129A1/fr
Application granted granted Critical
Publication of CA2329129C publication Critical patent/CA2329129C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002329129A 1998-05-22 1999-05-19 Formulations geniques stables Expired - Fee Related CA2329129C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10/141426 1998-05-22
JP14142698 1998-05-22
PCT/JP1999/002595 WO1999061063A1 (fr) 1998-05-22 1999-05-19 Preparations geniques stables

Publications (2)

Publication Number Publication Date
CA2329129A1 true CA2329129A1 (fr) 1999-12-02
CA2329129C CA2329129C (fr) 2009-02-24

Family

ID=15291718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002329129A Expired - Fee Related CA2329129C (fr) 1998-05-22 1999-05-19 Formulations geniques stables

Country Status (9)

Country Link
US (1) US7052875B1 (fr)
EP (2) EP1078639A4 (fr)
JP (1) JP4424850B2 (fr)
KR (1) KR100600464B1 (fr)
CN (1) CN1173744C (fr)
AU (1) AU755126B2 (fr)
CA (1) CA2329129C (fr)
NZ (1) NZ508785A (fr)
WO (1) WO1999061063A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US20040052840A1 (en) * 2000-06-20 2004-03-18 Shunichiro Kubota Preparations for oligonucleotide transfer
KR100888566B1 (ko) * 2001-06-20 2009-03-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 핵산 도입을 촉진시키는 방법
JP4954550B2 (ja) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 新規な核酸導入法
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
EP2236520A1 (fr) * 2009-03-31 2010-10-06 Leukocare Ag Composition de stabilisation pour biomolécules immobilisées
JP5908397B2 (ja) * 2009-06-09 2016-04-26 デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． 病原体感染を予防又は治療するためのインターフェロン投与
CN103221066A (zh) * 2010-10-15 2013-07-24 国立大学法人京都大学 缓释性药物组合物
US20120263681A1 (en) * 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer
CN116635520A (zh) * 2020-05-28 2023-08-22 隆萨有限公司 病毒载体的调配物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332900A (en) * 1980-10-01 1982-06-01 The Upjohn Company Construction of co-integrate plasmids from plasmids of Streptomyces and Escherichia
JPH0616690B2 (ja) * 1986-09-24 1994-03-09 キユーピー株式会社 水中油型乳化食品の製造方法
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
CA1338839C (fr) * 1988-01-29 1997-01-14 Yoshio Sasaki Formulation pour liberation-retard
JP2553198B2 (ja) * 1989-07-21 1996-11-13 帝人株式会社 安定化された粉末状カルシトニン類医薬組成物
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
JPH04370095A (ja) * 1991-06-19 1992-12-22 Kao Corp 澱粉加水分解酵素の安定化法
JP2971680B2 (ja) * 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH05331071A (ja) 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
JPH07173074A (ja) * 1993-10-27 1995-07-11 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
JPH08109140A (ja) * 1994-10-12 1996-04-30 Green Cross Corp:The 高血圧症予防治療剤
AU5417796A (en) 1995-03-07 1996-09-23 University Of Pittsburgh A dry powder formulation for gene therapy
EP0872249A4 (fr) * 1995-03-17 2001-10-24 Hisamitsu Pharmaceutical Co Preparation de transfert genique
EP0833667A4 (fr) * 1995-06-07 2001-11-21 Univ California Stabilisation de complexes de polynucleotides
JP3867160B2 (ja) 1995-07-03 2007-01-10 大日本住友製薬株式会社 遺伝子製剤
CN1230205C (zh) * 1995-07-03 2005-12-07 株式会社高研 基因制剂
WO1999045966A1 (fr) * 1998-03-13 1999-09-16 American Home Products Corporation Composition polynucleotidique, procede de preparation et utilisation

Also Published As

Publication number Publication date
EP1623723A2 (fr) 2006-02-08
KR20010043764A (ko) 2001-05-25
AU3848899A (en) 1999-12-13
EP1078639A1 (fr) 2001-02-28
US7052875B1 (en) 2006-05-30
EP1623723A3 (fr) 2006-05-10
CN1173744C (zh) 2004-11-03
KR100600464B1 (ko) 2006-07-13
NZ508785A (en) 2003-10-31
WO1999061063A1 (fr) 1999-12-02
CN1310632A (zh) 2001-08-29
EP1078639A4 (fr) 2004-10-06
AU755126B2 (en) 2002-12-05
JP4424850B2 (ja) 2010-03-03
CA2329129C (fr) 2009-02-24

Similar Documents

Publication Publication Date Title
CA2203033A1 (fr) Composes et compositions pour l'administration d'agents actifs
CA2318566A1 (fr) Aliments gelifies et procede de fabrication
IE940583L (en) Topical antimicrobial pharmaceutical compositions
CA2069153A1 (fr) Composition pharmaceutique
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
CA2152907A1 (fr) Compositions pharmaceutiques topiques antivirales
HUP0100284A2 (hu) Aktivált protein C készítmények
AU8170994A (en) Phospholipids as a vector for an active molecule, their preparation and their use in cosmetic or dermatological compositions
CA2081356A1 (fr) Derives et analogues de l'acide 2-desoxy-2,3-dideshydro-n-acetylneuraminique; leur utilisation comme agents antiviraux
HUT54144A (en) Process for producing 3-desmethylmevalonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
CA2009890A1 (fr) Acide valproique
HK1005224A1 (en) Use of complex lipide as stabilizing additives in pharmaceutical formulation of digestive enzyme mixture.
CA2123048A1 (fr) Derives tetrazole d'acides biliaires, procedes pour leur preparation et leur utilisation comme medicaments
CA2265767A1 (fr) Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane
IE852593L (en) Compositions containing anthracycline glycosides
CA2329129A1 (fr) Formulations geniques stables
CA2256410A1 (fr) Composition pharmaceutique stable du facteur bdnf
WO2003028623A3 (fr) Preparations pharmaceutiques servant au traitement de tumeurs et de lesions de la peau et des muqueuses et procedes et ensembles faisant intervenir ces preparations
CA2022177A1 (fr) Arginine deiminase, methode de production, et agent anti-cancereux contenant cette enzyme comme ingredient efficace
CA2175971A1 (fr) Composition liquide stable renfermant de l'urate-oxydase; composition lyophilisee pour sa preparation
CA2295628A1 (fr) Formulations stables contenant un nucleotide et un additif lyophilise
CA2234231A1 (fr) Formulation stabilisante pour le facteur humain de croissance nerveuse
AU5099400A (en) Microencapsulated and controlled-release herbal formulations
CA2238389A1 (fr) Nouveaux derives geranyl-geranyle, procede pour les preparer et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed